Early oncology clinical trial design in the era of molecular-targeted agents.
about
Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingAdaptive designs for identifying optimal biological dose for molecularly targeted agents.Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic orderingHER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
P2860
Early oncology clinical trial design in the era of molecular-targeted agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Early oncology clinical trial design in the era of molecular-targeted agents.
@en
Early oncology clinical trial design in the era of molecular-targeted agents.
@nl
type
label
Early oncology clinical trial design in the era of molecular-targeted agents.
@en
Early oncology clinical trial design in the era of molecular-targeted agents.
@nl
prefLabel
Early oncology clinical trial design in the era of molecular-targeted agents.
@en
Early oncology clinical trial design in the era of molecular-targeted agents.
@nl
P2093
P2860
P356
P1433
P1476
Early oncology clinical trial design in the era of molecular-targeted agents.
@en
P2093
Andre T Brunetto
Johann S de Bono
Rebecca S Kristeleit
P2860
P304
P356
10.2217/FON.10.92
P407
P577
2010-08-01T00:00:00Z